PROSPECT Phase 3 Clinical Study
PROSPECT is a global, randomized, double-blind, placebo-controlled phase 3 study being conducted under a Special Protocol Assessment (SPA) from the FDA. The objective of the study is to determine whether PROSTVAC® alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castration-resistant prostate cancer (mCRPC).
In December 2014, the study reached its enrollment target of 1,200 asymptomatic or minimally symptomatic mCRPC patients. Patients were enrolled at more than 200 sites in 15 countries, including Australia, Belgium, Canada, Denmark, Estonia, France, Germany, Iceland, Israel, Netherlands, Poland, Russia, Spain, United Kingdom and the United States.
Design of the PROSPECT Clinical Study
|Men with non/minimally symptomatic mCRPC (n=1200)||↗||PROSTVAC||↘||Long-term follow up||→||SURVIVAL|
|→||PROSTVAC + GM-CSF||→|
5 Months Treatment
Interim analysis plan
The PROSPECT study statistical analysis plan, accepted by the FDA under the SPA, includes prespecified interim analyses of data to evaluate whether the study should continue as planned or potentially be stopped early, either for efficacy or futility. If the study exceeds the efficacy threshold during an interim analysis, applications for product marketing approval may be filed with regulatory authorities at an earlier stage, potentially shortening the overall development time.
Additional details of the study can be found on http://clinicaltrials.gov/ct2/show/NCT01322490.